medicube PDRN Pink Peptide Eye Cream: Reading a 52-Ingredient Label Honestly

medicube's eye product arrives as a 30 ml pale-pink tube and is sold in the US under a serum name. The front of pack declares two things rather than gesturing at them: PDRN, glossed in brackets as sodium DNA, and niacinamide at 5%. The listing adds retinol described as 99% pure and a peptide blend, and the A+ panel ties all four to one promise about uneven, dull eye area — a different pitch from the wrinkle language most of this category uses.

At $18.90 for 30 ml it is priced per millilitre well below the prestige eye products it visually imitates, and the texture claim is the one the brand repeats everywhere: silky, lightweight, non-sticky, fast-absorbing. Directions are a pea-sized amount patted around the contour daily, without any ramp-up schedule — worth noting because the formula does contain retinol.

The three primary listing images, shown in carousel order. No buyer-uploaded photography accompanies this capture, so the gallery is the listing set only.

Individual review text was not rendered on this capture. The aggregate rating, the five-bucket histogram and the retailer's own aspect summary were all present, but no review card came back across the desktop, mobile and alternate-context passes. Nothing in this report quotes a review, and none was reconstructed.

Amazon's own aspect summary

Customers find this eye serum effective and hydrating, particularly around the delicate eye area, with one noting it provides long-lasting hydration without feeling greasy. The product receives positive feedback for its smooth texture, quick absorption without leaving residue, and ability to brighten and reduce darkness under the eyes. While some customers say it doesn't irritate their skin, others report irritation around their eyes, and opinions on value for money are mixed.

Mentions are counted by the retailer's own summariser across the review corpus; they are not a sample this report drew. An aspect at or near 50% is a split verdict, not a negative one.

Fifty-two positions is a long list for an eye product, and length here is doing marketing work: the four named actives sit at positions 4, 22, 38 and 47 to 52, which means most of the list is texture, emulsion and botanical colour rather than treatment. That is not a criticism by itself — a 30 ml product at this price has to be pleasant enough to use daily — but it does mean the interesting analysis is about where the treatment layer actually sits and how much of the list is unrated. The community ingredient database carries no entry for this formula at all, so this section reads the list two ways: by role, and by the only grades that are published.

What's inside

Composition by role

The community ingredient database does not index this formula, so no ingredient here carries a safety score and a safety-band count cannot be computed. The classification below instead groups all 52 positions by what they do in the formula, which is the reading the list itself supports. Risk is handled separately in the grades chart, using the only ratings that are published for this product.

These are the comedogenic and irritancy grades published by the consumer-claim database, and only 16 of 52 positions carry a figure on either axis. The large 'Not rated' column is coverage, not safety — it means the source publishes nothing for that ingredient, and reading it as a zero would be wrong in the same way reading an empty cell as a clean sheet would be.

Key ingredient groups

What the formula signals as concerns

• May Trigger Acne — Can clog pores or trigger breakouts.
• May Worsen Oily Skin — May increase shine or excess oil.
• May Worsen Rosacea — Can trigger flare-ups in rosacea-prone skin.

Benefit map

Complete ingredient table

Position follows the current INCI order on the pack. Safety, acne and irritant columns come from the community ingredient database; comedogenic and irritancy columns come from the consumer-claim database. Both sets are reproduced as published, including their disagreements.

Two coverage facts bound everything above. First, the safety database does not index this product, so no safety mean or safety band exists to report; the three medicube eye entries it does hold are the brand's 2022 peptide creams, which share no leading ingredients with this formula and were excluded rather than merged. Second, of 52 positions only 16 carry a published comedogenic grade and 16 a published irritancy grade. Everything else is unrated, and unrated is reported as unrated.

Price history as recorded by the public tracker

Movement over the monitored window

The tracker publishes turning points, not a continuous daily series, so the line below joins the dated observations it actually records. Gaps are real — the source records no intermediate value between them.

Method and limits

• Price, rank, rating, histogram and bullet copy were read from the US product page with a New York 10001 delivery context and native USD pricing; nothing was converted or estimated.
• Price history turning points were read from a public Amazon price tracker on the same date. They are all-time figures over a window opening March 2025, and the Amazon lane currently holds no current price.
• The ingredient list was transcribed from the brand's published panel and validated against two independent retailer copies of the same panel; all three agree position for position.
• No safety score exists for this formula in the community ingredient database. None was derived by analogy from similar products, and the three near-miss entries that do exist were excluded and documented.
• No buyer photography and no individual review text were available on this capture. Both gaps are stated where they occur.

Confidence by block

Compiled 2026-11-01. Prices, ranks and review counts move between captures; every figure here is a dated snapshot, not a standing quote.